Marijuana and Seizures: Evidence-Based Guidance
Direct Answer
FDA-approved cannabidiol (CBD) is effective for specific rare epilepsy syndromes, but whole-plant marijuana/cannabis is not FDA-approved for seizure control and carries significant risks that may outweigh uncertain benefits. 1, 2
FDA-Approved Cannabinoid for Epilepsy
Epidiolex (pharmaceutical-grade CBD) is the only cannabis-derived medication with FDA approval for epilepsy treatment. 1, 2 This approval is limited to three specific conditions:
- Dravet Syndrome - randomized controlled trials demonstrated significant seizure reduction compared to placebo 2, 3
- Lennox-Gastaut Syndrome - controlled trials showed significant improvement in seizure frequency 2, 3
- Tuberous sclerosis complex-associated seizures 1, 2
The typical dosing is 5-25 mg/kg/day administered twice daily, with dose-related, reversible transaminase elevations occurring in approximately 13% of patients, typically within the first 2 months 4
Critical Distinction: Medical Marijuana vs. FDA-Approved CBD
Medical marijuana itself has never received FDA approval for any indication, despite state-level legalization programs. 1, 5 Cannabis remains federally classified as Schedule I with "no currently accepted medical use" and "high potential for misuse." 1, 5
Key Differences:
- Pharmaceutical CBD (Epidiolex): Highly purified, standardized dosing, proven efficacy in controlled trials 2, 3
- Artisanal/dispensary cannabis products: Variable potency, uncontrolled THC content, lack of rigorous clinical trial data 3, 6
Evidence for Whole-Plant Cannabis in Epilepsy
Observational Data (Lower Quality Evidence):
Studies of patients using recreational/medical marijuana show:
- Perceived improvement: 84% of epilepsy patients reported subjective seizure improvement, though this was uncontrolled and may reflect stress reduction rather than direct anticonvulsant effects 7
- High usage rates: 57-64% of patients with uncontrolled epilepsy report marijuana use 7, 6
- Dosing uncertainty: Only 2 of 39 patients could provide exact dosing in milligrams 6
These observational studies cannot establish causation and are confounded by placebo effects, stress reduction, and variable product composition. 7, 8
Significant Safety Concerns
Seizure Precipitation Risk:
Whole-plant cannabis can paradoxically both contribute to and reduce seizures. 8 Five patients with epilepsy reported possible seizure precipitation from marijuana use 7
Hepatotoxicity with CBD:
- Liver enzyme monitoring is essential - meta-analysis showed 6-fold increase in liver enzyme elevation with CBD use 4
- No cases reported with total CBD doses <300 mg/day 4
- Risk increases with concomitant valproate - many patients with transaminase elevations were taking valproate simultaneously 3
Drug-Drug Interactions:
CBD significantly interacts with multiple antiepileptic drugs through CYP450 inhibition: 3
- Clobazam: CBD inhibits CYP2C19, significantly increasing N-desmethylclobazam levels and causing sedation 3
- Valproate: Increased risk of hepatotoxicity when combined 3
- Other interactions: Rufinamide, zonisamide, topiramate, eslicarbazepine, and warfarin 3
Cannabis Potency Concerns:
THC concentrations have nearly doubled from 9% (2008) to 17% (2017), with concentrates reaching 70% THC, dramatically increasing all health risks. 9
Standard Antiepileptic Drug Therapy Remains First-Line
For convulsive epilepsy, monotherapy with standard antiepileptic drugs (carbamazepine, phenobarbital, phenytoin, valproic acid) should be offered first. 10 Cannabinoids should only be considered after failure of standard therapies and only in FDA-approved indications.
Post-Cardiac Arrest Seizure Management
For seizures in other contexts (e.g., post-cardiac arrest), treat with sodium valproate, levetiracetam, phenytoin, benzodiazepines, propofol, or barbiturates - not cannabis products. 11 Prophylactic anticonvulsant drugs are not recommended due to poor response rates and adverse effects 11
Clinical Algorithm for Cannabis/Cannabinoid Use in Epilepsy
- Confirm diagnosis: Dravet Syndrome, Lennox-Gastaut Syndrome, or tuberous sclerosis complex 2
- Document treatment-resistant epilepsy: Failure of at least two standard antiepileptic drugs 3
- Use only FDA-approved pharmaceutical CBD (Epidiolex) - not dispensary products 1, 2
- Baseline liver function tests before initiating CBD 4
- Monitor transaminases monthly for first 2 months, then periodically 4
- Review all concomitant medications for CYP450 interactions, particularly clobazam and valproate 3
- Start low, titrate slowly to minimize adverse effects 4
Common Pitfalls to Avoid
- Do not recommend dispensary cannabis products - these lack standardization, quality control, and rigorous efficacy data 3, 6
- Do not assume patient-reported "CBD oil" is pharmaceutical-grade - most dispensary products contain variable THC and CBD ratios 6
- Do not ignore drug interactions - CBD is a potent CYP450 inhibitor requiring dose adjustments of other medications 3
- Do not skip liver monitoring - hepatotoxicity is dose-dependent and potentially serious 4
- Do not use in pregnancy - all cannabis products carry fetal brain development risks 1, 5
Populations Requiring Absolute Avoidance
Pregnant and breastfeeding individuals must avoid all cannabis products due to fetal neurodevelopmental risks and increased premature birth risk. 1, 5 Adolescents face elevated risks including neurodevelopmental decline, psychotic disorders, depression, and suicidal ideation 1, 5